Information for medical professionals only.
Internet Drug Information Service Certificate Number: (Lu)-non-commercial-2018-0066
Kexing Biopharm Establishes Holding Company for Developing Veterinary Vaccines
Release date:2022 - 03 - 15
Scientific Vaccine Innovations for Harmonious Coexistence Between Humans and Animals
Veterinary vaccines are not only a part of biopharmaceuticals but also the most important constituent of veterinary biological products. The future of veterinary vaccine technical development lies in genetic engineering. As an innovative biopharmaceutical enterprise, Kexing Biopharm Co., Ltd. (Kexing Biopharm) has rich experience in R&D management and well-established systems for R&D innovation of biological products. During our development of biopharmaceuticals, we actively focus on and plan for the cultivation and incubation of biotechnologies, aiming to make breakthroughs in vaccine R&D with the idea of "preventing and controlling human and animal diseases altogether".
Holding Company - A Veterinary Vaccine Developer
On the evening of March 14, 2022, we announced our investment in a holding company, Shenzhen Kexing Animal Health Biotechnology Co., Ltd. The company has a registered capital of RMB 10,909,000 and will focus on the R&D of veterinary vaccines. As stated in the announcement, we have signed the Joint Venture Agreement of Shenzhen Kexing Animal Health Biotechnology Co., Ltd. with Prof. Fu Jun and Prof. Ma Jingyun, which stipulates that the company shall be jointly funded by the three parties.
The focus of Shenzhen Kexing Animal Health Biotechnology will be to carry out R&D activities of veterinary vaccines, making full use of our rich experience and reputation in the biopharmaceutical field. In this way, we can seize the opportunity of biotechnology development, stimulate overall development, optimize our allocation of resources and enhance our core competitiveness.
Prof. Fu Jun
Fu Jun is a professor and doctoral supervisor at Shandong University. As a senior expert in genetic engineering, he has engaged in research on mechanisms and technologies of recombinase-mediated DNA homologous recombination, site-specific recombination and transposition. For this project, he will provide crucial technical support for the construction of a novel viral vector.
Prof. Ma Jingyun
Ma Jingyun is a professor and doctoral supervisor in the College of Animal Science, South China Agricultural University. She has been working with healthy animal husbandry and comprehensive disease prevention & control, mainly the epidemiology, diagnostic techniques and new vaccines of porcine viral diarrhea, porcine pseudorabies and porcine reproductive and respiratory syndrome. After decades of research on animal disease prevention and control, she has accumulated a wealth of experience in vaccine development and has cooperated with many leading enterprises in the industry, including Qilu Animal Health, Wens and Spirit Jinyu.
About Kexing BIOPHARM
Kexing Biopharm is an innovative biopharmaceutical enterprise mainly engaged in the R&D, production and sales of recombinant protein therapeutics and microecological agents. We focus on pharmaceutical research in the therapeutic fields of antiviral, oncology, immunology, hematology, digestion and degenerative diseases.which will benefit patients all over the world and help us turn into a leader in high-quality biologicals.
In recent years, we have achieved continued and rapid growth in its business, becoming a leader in the recombinant protein therapeutics industry. Our core products, remained at the forefront of similar varieties in China, have been adopted by over 18,000 sales terminals, including over 6500 hospitals in the provinces, municipalities and regions across China, and accessed into and sold in over 30 countries, including Brazil, Philippinesand Indonesia.
Share to:
Scan Code Consultation